These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18772338)

  • 1. Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling.
    Anderson CR; Hastings NE; Blackman BR; Price RJ
    Am J Pathol; 2008 Oct; 173(4):1220-8. PubMed ID: 18772338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shear stress modulates the expression of thrombospondin-1 and CD36 in endothelial cells in vitro and during shear stress-induced angiogenesis in vivo.
    Bongrazio M; Da Silva-Azevedo L; Bergmann EC; Baum O; Hinz B; Pries AR; Zakrzewicz A
    Int J Immunopathol Pharmacol; 2006; 19(1):35-48. PubMed ID: 16569344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.
    Kazerounian S; Duquette M; Reyes MA; Lawler JT; Song K; Perruzzi C; Primo L; Khosravi-Far R; Bussolino F; Rabinovitz I; Lawler J
    Blood; 2011 Apr; 117(17):4658-66. PubMed ID: 21378271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells.
    Chu LY; Ramakrishnan DP; Silverstein RL
    Blood; 2013 Sep; 122(10):1822-32. PubMed ID: 23896411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD36-TSP-HRGP interactions in the regulation of angiogenesis.
    Silverstein RL; Febbraio M
    Curr Pharm Des; 2007; 13(35):3559-67. PubMed ID: 18220792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes.
    Cursiefen C; Maruyama K; Bock F; Saban D; Sadrai Z; Lawler J; Dana R; Masli S
    J Exp Med; 2011 May; 208(5):1083-92. PubMed ID: 21536744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CD36 molecular features required for its in vitro angiostatic activity.
    Primo L; Ferrandi C; Roca C; Marchiò S; di Blasio L; Alessio M; Bussolino F
    FASEB J; 2005 Oct; 19(12):1713-5. PubMed ID: 16037098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway.
    Ren B; Hale J; Srikanthan S; Silverstein RL
    Blood; 2011 Jun; 117(22):6036-45. PubMed ID: 21441463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD36: a critical anti-angiogenic receptor.
    Simantov R; Silverstein RL
    Front Biosci; 2003 Sep; 8():s874-82. PubMed ID: 12957861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.
    Koch M; Hussein F; Woeste A; Gründker C; Frontzek K; Emons G; Hawighorst T
    Breast Cancer Res Treat; 2011 Jul; 128(2):337-46. PubMed ID: 20714802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36.
    Yang M; Li K; Ng MH; Yuen PM; Fok TF; Li CK; Hogg PJ; Chong BH
    Thromb Res; 2003 Jan; 109(1):47-54. PubMed ID: 12679131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth.
    Hale JS; Li M; Sinyuk M; Jahnen-Dechent W; Lathia JD; Silverstein RL
    PLoS One; 2012; 7(7):e40033. PubMed ID: 22808089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway.
    Bussolati B; Assenzio B; Deregibus MC; Camussi G
    J Mol Med (Berl); 2006 Oct; 84(10):852-63. PubMed ID: 16924472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
    Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
    Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
    Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
    Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina.
    Sun J; Hopkins BD; Tsujikawa K; Perruzzi C; Adini I; Swerlick R; Bornstein P; Lawler J; Benjamin LE
    Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1344-51. PubMed ID: 19304944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.
    Yafai Y; Eichler W; Iandiev I; Unterlauft JD; Jochmann C; Wiedemann P; Bringmann A
    Ophthalmic Res; 2014; 52(2):81-8. PubMed ID: 25138030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake.
    Isenberg JS; Jia Y; Fukuyama J; Switzer CH; Wink DA; Roberts DD
    J Biol Chem; 2007 May; 282(21):15404-15. PubMed ID: 17416590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36.
    Yehualaeshet T; O'Connor R; Green-Johnson J; Mai S; Silverstein R; Murphy-Ullrich JE; Khalil N
    Am J Pathol; 1999 Sep; 155(3):841-51. PubMed ID: 10487979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36.
    Klenotic PA; Page RC; Li W; Amick J; Misra S; Silverstein RL
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1655-62. PubMed ID: 23640500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.